Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Enasidenib in Hepatic Impairment
NCT04573582Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enasidenib in acute myeloid leukemia (AML) (4 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration of Enasidenib (CC-90007) at Day 1, Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (CC-90007) and 2 more. Started Nov 2020; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04573582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573582.